Interventional Cardiology

This cardiac subspecialty uses minimally invasive, catheter-based technologies in a cath lab to diagnose and treat coronary artery disease (CAD). The main focus in on percutaneous coronary interventions (PCI) to revascularize patients with CAD that is causing blockages resulting in ischemia or myocardial infarction. PCI mainly consists of angioplasty and implanting stents. Interventional cardiology has greatly expanded in scope over recent years to include a number of transcatheter structural heart interventions.

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device
The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.
First 250 patients treated with transcatheter heart failure device to reduce LV size
The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.
Angiographic catheters recalled due to safety risk
The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use.
TAVR patients with moderate or greater TR may face increased risks
When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.
Robotic heart surgery represents a key step forward for SS Innovations
The company's SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.

EnCompass F2 device from Nevada-based EnCompass Technologies

A closer look at world’s first TAVR patient treated with new cerebral embolic protection device

The device covers three vessels at once and can be deployed through the patient's TAVR access site. Researchers shared their first-in-human experience in JACC: Case Reports.

Ancora Heart AccuCinch Ventricular Restoration System heart failure FDA

First 250 patients treated with transcatheter heart failure device to reduce LV size

The first 250 patients has been enrolled in the CORCINCH-HF U.S. pivotal trial evaluating the AccuCinch Transcatheter Left Ventricular Restoration System in patients with HFrEF.

Cook Medical angiographic catheter recall

Angiographic catheters recalled due to safety risk

The new Class I recall includes nearly 27,000 devices that could potentially experience a harmful defect during use.

heart data research doctor cardiologist AI

TAVR patients with moderate or greater TR may face increased risks

When TAVR patients present with moderate or greater tricuspid regurgitation, it could impact the care team's treatment strategy of choice.

SS Innovations International SSi Mantra 3 robotic surgery system

Robotic heart surgery represents a key step forward for SS Innovations

The company's SSi Mantra 3 robotic surgery system has already gained regulatory approvals in several countries. FDA approval is anticipated by late 2025 or early 2026.

Statue of Liberty New York City healthcare

Late-breaking clinical trials announced for New York Valves 2025

The three-day event is now in its second year. Each day will feature late-breaking clinical trials focused on a different heart valve.

Next-day discharge after TAVR is still safe when alternative access is required

Even TAVR patients not treated using transfemoral access can typically go home the very next day.

Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution

The EARLY TAVR clinical trial made a significant impact, paving the way for the FDA to approve multiple transcatheter heart valves for the treatment of asymptomatic patients. However, one cardiologist who participated in the trial has some serious concerns with how its findings were presented to the public.